How to get FDA's List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic

-

                                                  


The FDA maintains a list of approved new drug application (NDA) drug products that are no longer protected by patents or exclusivities, and for which the FDA has not approved an abbreviated new drug application (ANDA) referencing that NDA product. The FDA updates this list every six months (in June and December) to improve transparency and encourage the development and submission of ANDAs in markets with little competition.

 The list is separated into three sections:

  • Part I identifies those drug products for which FDA could immediately accept an ANDA without prior discussion.
  • Part II identifies drug products for which ANDA development or approval may raise potential legal, regulatory, or scientific issues that should be addressed with the Agency prior to considering submission of an ANDA.
  • The Appendix identifies NDA drug products that were removed from Part I or Part II of the list because one or more ANDAs referencing such NDA drug products have been approved since the previous list publication.

 

The list will provide the information regarding the ingredient, approved NDA number and dosage form details as below for reference.


                 


Currently, December 2020 List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic is available, refer below link

https://www.fda.gov/media/144502/download


Comments

Post a Comment

Popular posts from this blog

Top 10 Pharma Industry Trends & Innovations in 2021

-
Image
                                          Top 10 Pharma Industry Trends & Innovations in 2021 The COVID pandemic has forced all companies to rethink many aspects of their business, including manufacturing and the same holds true for pharma companies. The pandemic also highlights the need for improving the speed and accuracy of finding and mass-producing novel drugs, treatment methods, and vaccines to respond to such large-scale and high-pressure demand. Below are most relevant solution  1. Artificial Intelligence and Machine Learning The use of artificial intelligence and machine learning is accelerating the drug discovery and development processes. Pharma industries are exploring the use of these technologies to address the various challenges, such as automation and optimization of the manufacturing processes, as well as designing effective marketi...
Read more

Nitrosamine Impurities: API & Pharmaceutical Products

-
Image
                                     Nitrosamine Impurities: API & Pharmaceutical Products The Sartans case substantiates the necessity for the pharmaceutical industry to improve the standards on application of risks management tools, particularly regarding post approval activities. The case also showed some of the potential risks associated with the lack of transparency between MAHs, API manufacturers, and others over patient safety and the shift required to increase transparency through revisions of the regulatory framework whilst ensuring safeguarding of confidential information.   Medicine regulatory authorities were alerted of the presence of the nitrosamine impurity, N-nitrosodimethylamine (NDMA), in products containing valsartan in July 2018. Valsartan is an Angiotensin II Receptor Blocker (ARB) belonging to a class of products commonly referred to as sartans. ...
Read more

Pharmaceutical Deformulation / Reverse Engineering of a Product’s Formulation

-
Image
                                                              Pharmaceutical  D eformulation / Reverse Engineering of a Product’s Formulation   Step 5: Formulation and process development… Cont….   https://pharmatutor21.blogspot.com/2021/02/generic-product-development-key-steps-l_7.html Understanding of RLD product:   Understanding of information available in ‘Label’ section The PIL/Label will provide the information regarding the qualitative composition of the formulation. In this case qualitative formulation of Table and Oral Solution. Let us explore the Tablet formulation.               Step-1:              From the PIL, we can get the information              ...
Read more